Travere Therapeutics Inc. Revenue 2011–2025
Travere Therapeutics Inc. annual/quarterly revenue history and growth rate from 2011 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Travere Therapeutics Inc. revenue for the quarter ending March 31, 2026 was 127.2 M, a 55.63% increase year-over-year.
- Travere Therapeutics Inc. revenue for the twelve months ending March 31, 2026 was 488.2 M, a 149.76% increase year-over-year.
- Travere Therapeutics Inc. annual revenue for 2025 was 490.7 M, a 110.45% increase from 2024.
- Travere Therapeutics Inc. annual revenue for 2024 was 233.2 M, a 60.55% increase from 2023.
- Travere Therapeutics Inc. annual revenue for 2023 was 145.2 M, a 32.69% increase from 2022.
- Travere Therapeutics Inc. annual revenue for 2022 was 109.5 M.
Travere Therapeutics Inc. (TVTX) — Frequently Asked Questions
Travere Therapeutics Inc. (TVTX) is a publicly traded US company. It has a market capitalization of $4.17B. In fiscal 2025 it reported revenue of $491M and net income of -$26M. Explore TVTX's stock price, financial statements, earnings history, margins and key ratios below.
What is Travere Therapeutics Inc.'s market cap?
Travere Therapeutics Inc. (TVTX) has a market capitalization of $4.17B.
What is the TVTX stock price?
TVTX trades at $46.74 (-3.77% on the day).
How much revenue does Travere Therapeutics Inc. make?
Travere Therapeutics Inc. reported revenue of $491M in fiscal 2025.
Is TVTX profitable?
In fiscal 2025, Travere Therapeutics Inc. reported net income of -$26M.